The ART program, administered through the NSF Directorate for Technology, Innovation and Partnerships, was created to build capacity for translational research at institutions of higher education across the full geographic breadth of the United States. Rather than funding a single laboratory or a narrow line of inquiry, the program invests in institutional ecosystems: the offices, training programs, mentorship networks and cultural incentives that determine whether a promising result in a journal ever becomes a licensed technology, a startup or a product on the market. NSF’s stated goal is to advance American scientific and economic leadership by increasing the number of robust translational research ecosystems nationwide, and Portland State’s award is one piece of that national strategy.

University President Ann Cudd framed the grant in terms of the institution’s founding ethos. Portland State’s motto, she noted, is ‘Let Knowledge Serve the City,’ and the award is intended to put that commitment to work for the regional economy. ‘Our researchers are producing discoveries with real commercial and civic value,’ Cudd said. ‘This investment helps us turn more of that work into Oregon companies, Oregon jobs and Oregon solutions.’ The emphasis on civic value as well as commercial return reflects the university’s identity as an urban public institution embedded in Portland’s downtown, where the boundaries between campus and city are unusually porous.

The grant will be executed through Propel PSU, the university division that unifies innovation, entrepreneurship and technology commercialization under a single organizational roof and a single leader. Propel PSU operates from a newly renovated building at the heart of Portland’s entrepreneurship district and houses several distinct but connected assets. Among them is the Portland State Business Accelerator, which has incubated more than 140 community startups across a range of sectors, and the Oregon AI Accelerator, which is preparing to accept its second cohort of 20 companies using artificial intelligence to build products across industries. The division also includes the university’s Innovation and Intellectual Property department, which functions as the technology transfer office, and the Center for Entrepreneurship, which delivers entrepreneurship education to students both at Portland State and across the state.

A fifth component, the Portland Metro Region Innovation Hub, is one of nine regional hubs funded through a statewide Business Oregon program and connects more than 400 traded-sector entrepreneurs to regional resources each year. Joseph Janda, Portland State’s assistant vice president for Innovation and the principal investigator on the award, argued that the pieces of a translation pipeline already exist and that the grant will knit them together with new intentionality. ‘We have built an array of economic-development infrastructure in Propel PSU, and we know PSU has a research portfolio that is ready to translate,’ Janda said. ‘This award lets us connect that infrastructure to PSU projects deliberately and with depth, so that more PSU discoveries become products, licenses, startups and industry partnerships that benefit Portland and the state.’

The project is organized around three coordinated strategies, each targeting a different stage of the journey from bench to market. The first, called Cultivate, aims to build a campus culture that identifies and rewards translational research. It will be led by a network of faculty members designated as ART Ambassadors and supported by revisions to promotion and tenure guidelines, an acknowledgment that faculty career incentives have historically favored publications and citations over patents, licenses and company formation. The second strategy, Elevate, develops promising discoveries through internal seed grants, expanded capacity for evaluating the commercial readiness of early-stage technologies, and a training program for graduate students and postdoctoral researchers designed to prepare the next generation of innovation talent.

The third strategy, Accelerate, addresses the later and often most difficult stage of commercialization, moving startups and projects toward customers, revenue and investment. It will provide intensive coaching at the Portland State Business Accelerator and dedicated navigation to a regional network of more than 160 capital providers, industry partners and support organizations. For early-stage companies, access to this kind of curated network can be decisive: seed-stage ventures frequently fail not because the underlying technology is weak but because founders lack connections to the angel investors, strategic partners and experienced operators who can convert a prototype into a viable business.

Three inaugural seed projects illustrate the breadth of the university’s pipeline and its alignment with regional industry strengths. The first is a resource-efficient single-photon LiDAR system being developed in collaboration with sensor manufacturers for robotics and mobile applications. Single-photon LiDAR, which detects individual returning photons to measure distances with extreme sensitivity, promises dramatically lower power consumption than conventional laser ranging, a critical advantage for battery-powered robots and mobile devices where every milliwatt matters. The second is a non-invasive, wearable glucose sensor being validated with Oregon Health & Science University and an industry partner, a technology that could spare people with diabetes the finger-prick blood sampling that has defined glucose monitoring for decades. The third is a hand-held satellite ground station with both commercial and STEM-education applications, built on the university’s OreSat satellite program, which puts low-cost small-satellite technology into the hands of students and potential commercial users alike.

To guide its efforts, Portland State will draw on Oregon State University as a mentor institution. Oregon State is recognized nationally as a leader in research commercialization, and the mentorship arrangement reflects a deliberate design feature of the ART program: institutions newer to large-scale translation are paired with peers that have already built the legal, financial and cultural machinery for moving research out of the lab. The award also operationalizes the fourth strategic imperative of Future in Focus, Portland State’s strategic plan, which commits the university to driving Portland’s economic, social and cultural resurgence by building research partnerships with regional industries, entrepreneurs and public agencies and by positioning the university as a gateway to Portland for talent and opportunity.

For the Portland metropolitan region, the significance of the grant extends beyond the dollar figure. The area’s economy has historically leaned on traded-sector industries such as semiconductors and outdoor gear, and civic leaders have long sought to deepen the pipeline of homegrown technology companies rooted in local research institutions. By tying a record federal investment to a structured program of faculty incentives, seed funding, founder training and investor access, Portland State is betting that the region’s next generation of companies can be grown, at least in part, from its own laboratories. Whether the bet pays off will be measured over the three years of the award in the currency that matters most to translational research: licenses signed, startups launched and jobs created in Oregon.

Subject of Research: A $5.9 million NSF Accelerating Research Translation grant to Portland State University for translating university research into regional economic development

Article Title: New $5.9M NSF grant powers up Portland State

Article References: New $5.9M NSF grant powers up Portland State. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Portland State University, National Science Foundation, research translation, technology transfer, economic development, entrepreneurship, LiDAR, wearable glucose sensor, startups, Oregon, artificial intelligence, seed funding

The quantitative texture of the interviews reinforces the qualitative alarm. When researchers coded the sentiment expressed across all of the conversations, they found that 74 percent of coded sentiment statements were negative. That figure is remarkable for a sector that is frequently celebrated as a pillar of Europe’s future economic strategy, and it suggests that the pessimism is not the grumbling of a vocal minority but a systemic assessment shared across the innovation chain. Crucially, the respondents did not attribute the sector’s difficulties to a single failing. Instead, they identified multiple structural bottlenecks that compound one another at every stage of the journey from laboratory discovery to market-ready product. The report frames these failures through the well-established concept of “valleys of death,” the perilous transitional phases in which promising scientific ideas and young companies routinely perish before reaching commercial viability.

The first valley of death concerns translation: the process of converting scientific discoveries into viable, financeable companies. Here the report offers a genuinely paradoxical picture. German and European biotechnology research is described as world-class, with the underlying science fully capable of anchoring a globally competitive industry. Yet the machinery that should carry that science out of universities and research institutes and into the hands of entrepreneurs is badly malfunctioning. Technology transfer offices, the institutional intermediaries responsible for licensing discoveries and supporting spinout formation, received a positive assessment from only 17 percent of respondents. That overwhelming dissatisfaction points to offices that too often act as bureaucratic gatekeepers rather than enablers, imposing slow procedures, inconsistent licensing terms, and limited commercial expertise on researchers who are attempting to move at the speed that competitive markets demand.

The second valley of death opens when young companies need substantially larger amounts of capital to develop and scale their technologies. It is at this stage that Europe’s disadvantage relative to the United States becomes most visible and most consequential. According to market data cited in the report, European venture capital funds account for only around seven percent of the global life sciences venture capital market, while US funds command 63 percent. That imbalance shapes corporate geography in tangible ways. Several founders interviewed for the report said that US investors made the establishment of a US entity or subsidiary a condition for participating in later financing rounds. Six of the eight founders questioned on this specific issue had already considered moving part of their operations to the United States, a migration of entrepreneurial activity that, once it begins, tends to be self-reinforcing as talent, suppliers, and follow-on capital cluster around the relocated companies.

What gives the report its distinctive tension is the argument that this grim picture coexists with a genuine, but temporary, opportunity. The authors cite market data showing that some areas of early-stage financing in the US biotechnology sector declined by 38 percent between the first quarters of 2025 and 2026. Several of the experts interviewed view this American retrenchment as a window during which Europe could capture deal flow, talent, and momentum that would otherwise flow to Boston, San Francisco, and other established US biotech hubs. The opportunity is conditional, however. It exists only if the necessary reforms are implemented now, while American investors are pulling back. Encouragingly, almost half of those interviewed expressed optimism that Europe can close the gap, suggesting that the pessimism documented in the sentiment analysis reflects frustration with current structures rather than despair about the continent’s underlying potential.

De Véricourt frames the stakes in explicitly strategic terms. “The window is closing rapidly. If we do not act now, we will not only lose individual companies to the United States. We risk permanently losing our ability to build internationally competitive biotech companies from our own research. In the long term, this would also weaken our ability to pursue fundamental research,” he says. The causal chain he describes runs in both directions: strong company formation justifies and funds fundamental research, while the erosion of the commercial pathway eventually starves the scientific base itself. For a continent that has staked much of its economic future on strategic sovereignty in critical technologies, the prospect of a permanently atrophied biotech sector carries implications that extend well beyond the industry’s own balance sheets, touching public health preparedness, industrial resilience, and the attractiveness of European research careers.

Perhaps the report’s most important diagnostic conclusion is what the problem is not. The authors are clear that the issue is not primarily a lack of research, funding programs, or institutions. Europe has scientists, it has grants, and it has agencies. What matters, the report argues, is whether existing resources are deployed in the right form, at the right time, and with a clear focus on successful company formation and growth. “More of the same will not be enough. The underlying structures and incentives must change,” de Véricourt adds. This framing shifts the policy debate away from the familiar demand for larger budgets and toward the harder work of institutional redesign: rewiring incentives so that universities, investors, and public programs are rewarded for producing companies that survive and scale rather than for the volume of patents filed or grants disbursed.

On the financing and scaling side, the report’s priorities include mobilizing institutional capital from pension funds, insurers, and other pools of long-term capital that currently sit largely on the sidelines of European venture investing. It also calls for more reliable tax incentives for private venture capital, giving individual investors and funds a predictable framework for backing risky early-stage science. A third proposal would establish a pan-European biotech listing segment, a dedicated public-market venue that would allow European companies to secure later-stage growth financing and complete initial public offerings on European exchanges. The strategic logic is direct: today, a European biotech that needs serious scale-up capital typically faces a choice between being acquired by a large pharmaceutical company or listing in the United States, and either outcome exports the value created by European science. A functioning European listing venue would keep that value, and the companies that generate it, inside the European economy.

The recommendations for the earliest stages of company formation are equally concrete. The report proposes opening public funding programs to companies that do not originate from universities, acknowledging that valuable biotech ventures can emerge from paths other than academic spinouts. It urges faster access to initial financing for founders, faster company formation through digital procedures, and fewer notarial and administrative hurdles, the accumulated friction that can add weeks or months to the incorporation of a startup in parts of Europe. Interviewees further emphasize the need to connect founders more systematically with investors, experienced entrepreneurs, and the pharmaceutical industry, building the relational infrastructure that in the United States has historically compensated for formal gaps in the system. On the translation side, the report recommends independent, professionally run translation institutes to complement existing university technology transfer structures, supporting research teams early with validation, team building, and financing. Technology transfer offices themselves should evolve from gatekeepers into facilitators, adopting standardized licensing terms, faster procedures, and stronger commercial expertise. The report builds on a 2025 predecessor, “Assessing Deep-Tech Innovation Hubs in Germany: The Case of Biotechnology,” which assessed Germany’s biotech innovation performance through a comprehensive index, and together the two documents sketch both the scale of the problem and a detailed roadmap for solving it before the window closes.

Subject of Research: Structural barriers to biotechnology innovation and company formation in Germany and Europe

Article Title: Concern over European biotech: the window for change is narrow – and closing fast

Article References: Concern over European biotech: the window for change is narrow – and closing fast. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: biotechnology, Europe, venture capital, technology transfer, startups, ESMT Berlin, valleys of death, strategic sovereignty, innovation policy, Germany, pharmaceutical industry, reform proposals